Literature DB >> 1702325

Interleukin-8 production in red blood cell incompatibility.

R D Davenport1, R M Strieter, T J Standiford, S L Kunkel.   

Abstract

Hemolytic transfusion reactions (HTR) are characterized by fever, shock, organ system failure, intravascular coagulation, and possibly death. The same findings may be associated with sepsis. Neutrophils have been implicated in the pathogenesis of HTR, although a mechanism for neutrophil activation has not been shown. In addition, the possible role that cytokines may play in HTR has not been investigated. We show that interleukin-8 (IL-8), a cytokine with chemotactic and neutrophil-activation properties, is produced in whole blood following addition of ABO-incompatible red blood cells, in a dose- and time-dependent manner related to the degree of hemolysis, and is inhibited by inactivation of complement. IL-8 production is accompanied by increased gene expression in the buffy coat. This observation has implications for the understanding of the pathogenesis of and for the treatment of HTR.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1702325

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  6 in total

1.  New frontiers in transfusion biology: identification and significance of mediators of morbidity and mortality in stored red blood cells.

Authors:  Katie Grimshaw; Julie Sahler; Sherry L Spinelli; Richard P Phipps; Neil Blumberg
Journal:  Transfusion       Date:  2011-04       Impact factor: 3.157

2.  Neutrophil attractant protein-1-immunoglobulin G immune complexes and free anti-NAP-1 antibody in normal human serum.

Authors:  I Sylvester; T Yoshimura; M Sticherling; J M Schröder; M Ceska; P Peichl; E J Leonard
Journal:  J Clin Invest       Date:  1992-08       Impact factor: 14.808

3.  The IgG-specific endoglycosidase EndoS inhibits both cellular and complement-mediated autoimmune hemolysis.

Authors:  Maria Allhorn; Juana G Briceño; Lucie Baudino; Christian Lood; Martin L Olsson; Shozo Izui; Mattias Collin
Journal:  Blood       Date:  2010-03-31       Impact factor: 22.113

4.  Severe Acute Hemolytic Transfusion Reaction Treated with Ruxolitinib and Plasma Exchange.

Authors:  Burak Deveci; Rabin Saba; Husnu Altunay; Tayfur Toptas; George Kublashvilli; Ihsan Karadogan
Journal:  Transfus Med Hemother       Date:  2021-01-08       Impact factor: 3.747

Review 5.  Red blood cell alloimmunization in sickle cell disease: pathophysiology, risk factors, and transfusion management.

Authors:  Karina Yazdanbakhsh; Russell E Ware; France Noizat-Pirenne
Journal:  Blood       Date:  2012-05-04       Impact factor: 22.113

6.  A case of ABO-incompatible blood transfusion treated by plasma exchange therapy and continuous hemodiafiltration.

Authors:  Akio Namikawa; Yuko Shibuya; Haruki Ouchi; Hiroko Takahashi; Yoshitaka Furuto
Journal:  CEN Case Rep       Date:  2018-01-31
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.